11:55 AM EST - ProMetic Life Sciences Inc. : announced today the signing of two strategic agreements with Shenzhen Hepalink Pharmaceutical Co., Ltd. The commercial agreement relates to a research and development project based on ProMetic's proprietary protein technologies and includes $11 million in licensing fees and milestone payments to ProMetic, of which $2 million is payable upfront. In addition, ProMetic shall receive further funding for product development activities to be performed on behalf of Hepalink, expected to be initiated in the fourth quarter of 2012. ProMetic Life Sciences Inc.
shares T.PLI are trading up $0.015 at $0.14.
